References
- Hardy C L, Balducci L. Hemopoietic alterations of cancer. Am J Med Sci 1985; 290: 196–205
- Balducci L, Hardy C. High proliferation of granulocyte-macrophage progenitors in tumor-bearing mice. Cancer Res 1983; 43: 4643–4647
- Hardy C L, Balducci L. Early hemopoietic events during tumor growth in mice. J Natl Cancer Inst 1986; 76: 535–540
- Skipper H E. Cancer Chemotherapy, Lewis Lung Carcinoma. Kettering-Meyer Laboratory of Southern Research Institute, Birmingham, AL 1979; Vol. 6
- Robins R K, Strivastava P C, Narayanan V L, et al. 2-β-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J Med Chem 1982; 25: 107–108
- Sanders P, Kuttan P. R, Lai M M, et al. Action of 2-β-D-riboruranosyltbJazole-4-carboxamide (tiazofurin) in Chinese hamster ovary and variant cell lines. Mol Pharmacol 1983; 23: 534–539
- Jayaram H N, Dion R L, Glazer R I, et al. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-D-ribofuranosyltruazole-4-carboxamide (NSC 286193). Biochem Pharmacol 1982; 31: 2371–2380
- Jayaram H N, Smith A L, Glazer R I, et al. Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC-286193) II. Relationship between dose-level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 1982; 31: 3839–3845
- Cooney D A, Jayaram H N, Gebeyeher G, et al. The conversion of 2-β-D-ribofuranosylmiazole-4-carboxamkle to an analogue of NAD with IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 1982; 31: 2133–2136
- Earle M F, Glazer R I. Activity and metabolism of 2-β-D-ribofuranosylthiazole-4-carboxamide in human lymphoid tumor cells in culture. Cancer Res 1983; 43: 133–137
- Trump D L, Tutsch K D, Koeller J M, et al. Phase I clinical study with pharmacokinetic analysis of 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. Cancer Res 1985; 45: 2853–2858
- Melink T J, Von Hoff D D, Kuhn J G, et al. Phase I evaluation of pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 1985; 45: 2859–2865
- Clinical Brochure. Tiazofurin. National Cancer Institute, Bethesda, MD 1983, March
- Till J E, McCulloch E A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213–222
- Magli M C, Iscove N N, Odartchenko N. Transient nature of early hemopoietic spleen colonies. Nature 1982; 295: 527–529
- Bradley T R, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44: 287–300
- Gregory C I. Erythropoietin sensitivity as a differentiation marker in hemopoietic systems: Studies of three erythropoietic colony responses in culture. J Cell Physiol 1979; 89: 289–301
- Humphries R K, Eaves A C, Eaves C J. Characterization of a primitive erythropoietic progenitor found in mouse marrow before and after several weeks in culture. Blood 1979; 53: 746–763
- Iscove N N, Sieber F. Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture. Exp Hematol 1975; 3: 32–43
- Kaplan E L, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 1966; 50: 163–170
- Morrison D V. Multivariate Statistical Methods. McGraw-Hill, New York 1967
- DeWys W D. A quantitative model for the study of the growth and treatment of a tumor and its metastases with correlation between proliferative state and sensitivity to cyclophosphamide. Cancer Res 1972; 32: 367–373
- Asluwalia G S, Jayaram H N, Plowman J P, et al. Studies of the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide-V. Factors governing the response of murine tumors to tiazofurin. Biochem Pharmacol 1984; 33: 1195–1203
- Jayaram H N, Johns D G. Metabolic and mechanistic studies with tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide). Developments in Cancer Chemotherapy, R I Glazer. CRC Press, Boca Raton 1984; 115–130
- Frei E HI. Curative cancer chemotherapy. Cancer Res 1985; 45: 6523–6537
- Marsh J C. The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells. Cancer Res 1976; 36: 1853–1882
- DeWys W D, Mansky J M. Delayed hematological recovery after cyclophosphamide treatment in the presence of an advanced tumor. Cancer Res 1973; 33: 2662–2667